DERM
Price
$7.16
Change
+$0.05 (+0.70%)
Updated
Jul 17 closing price
Capitalization
197.15M
24 days until earnings call
Intraday BUY SELL Signals
RDY
Price
$12.60
Change
-$0.10 (-0.79%)
Updated
Jul 17 closing price
Capitalization
10.69B
4 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DERM vs RDY

DERM vs RDY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DERM vs. RDY commentary
Jul 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DERM is a Hold and RDY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2026
Stock price -- (DERM: $7.16 vs. RDY: $12.60)
Brand notoriety: DERM: Notable vs. RDY: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DERM: 13% vs. RDY: 53%
Market capitalization -- DERM: $197.15M vs. RDY: $10.69B
DERM [@Pharmaceuticals: Generic] is valued at $197.15M. RDY’s [@Pharmaceuticals: Generic] market capitalization is $10.69B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DERM’s FA Score shows that 0 FA rating(s) are green whileRDY’s FA Score has 2 green FA rating(s).

  • DERM’s FA Score: 0 green, 5 red.
  • RDY’s FA Score: 2 green, 3 red.
According to our system of comparison, both DERM and RDY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DERM’s TA Score shows that 4 TA indicator(s) are bullish while RDY’s TA Score has 5 bullish TA indicator(s).

  • DERM’s TA Score: 4 bullish, 3 bearish.
  • RDY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, DERM is a better buy in the short-term than RDY.

Price Growth

DERM (@Pharmaceuticals: Generic) experienced а +3.62% price change this week, while RDY (@Pharmaceuticals: Generic) price change was -4.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.03%. For the same industry, the average monthly price growth was +0.74%, and the average quarterly price growth was +18.46%.

Reported Earning Dates

DERM is expected to report earnings on Aug 11, 2026.

RDY is expected to report earnings on Jul 22, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.03% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($10.7B) has a higher market cap than DERM($197M). DERM has higher P/E ratio than RDY: DERM (39.08) vs RDY (23.12). DERM YTD gains are higher at: -7.134 vs. RDY (-9.723). RDY has higher annual earnings (EBITDA): 79.2B vs. DERM (-1.42M). RDY has higher revenues than DERM: RDY (336B) vs DERM (64.7M).
DERMRDYDERM / RDY
Capitalization197M10.7B2%
EBITDA-1.42M79.2B-0%
Gain YTD-7.134-9.72373%
P/E Ratio39.0823.12169%
Revenue64.7M336B0%
Total Cash27.2MN/A-
Total Debt25.5MN/A-
FUNDAMENTALS RATINGS
DERM vs RDY: Fundamental Ratings
DERM
RDY
OUTLOOK RATING
1..100
8659
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
24
Undervalued
PROFIT vs RISK RATING
1..100
9398
SMR RATING
1..100
9865
PRICE GROWTH RATING
1..100
4470
P/E GROWTH RATING
1..100
4329
SEASONALITY SCORE
1..100
n/a7

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RDY's Valuation (24) in the Pharmaceuticals Generic industry is in the same range as DERM (55) in the Biotechnology industry. This means that RDY’s stock grew similarly to DERM’s over the last 12 months.

DERM's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as RDY (98) in the Pharmaceuticals Generic industry. This means that DERM’s stock grew similarly to RDY’s over the last 12 months.

RDY's SMR Rating (65) in the Pharmaceuticals Generic industry is somewhat better than the same rating for DERM (98) in the Biotechnology industry. This means that RDY’s stock grew somewhat faster than DERM’s over the last 12 months.

DERM's Price Growth Rating (44) in the Biotechnology industry is in the same range as RDY (70) in the Pharmaceuticals Generic industry. This means that DERM’s stock grew similarly to RDY’s over the last 12 months.

RDY's P/E Growth Rating (29) in the Pharmaceuticals Generic industry is in the same range as DERM (43) in the Biotechnology industry. This means that RDY’s stock grew similarly to DERM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DERMRDY
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
62%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
55%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
53%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 23 days ago
46%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 2 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
38%
View a ticker or compare two or three
Interact to see
Advertisement
DERM
Daily Signal:
Gain/Loss:
RDY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIDFX37.90N/A
N/A
Fidelity Advisor Mid Cap Value Z
LPFCX4.37N/A
N/A
ALPS Global Opportunity C
RTDAX14.42N/A
N/A
Russell Inv Multifactor US Equity A
OAZWX25.93-0.19
-0.73%
Oakmark Global Select R6
MEMFX43.27-0.62
-1.41%
MFS Emerging Markets Equity R2

DERM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DERM has been loosely correlated with APUS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DERM jumps, then APUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
+0.70%
APUS - DERM
49%
Loosely correlated
+0.76%
CHRS - DERM
27%
Poorly correlated
+0.72%
CRDL - DERM
23%
Poorly correlated
-1.63%
AMLX - DERM
23%
Poorly correlated
+4.29%
ETON - DERM
23%
Poorly correlated
+13.79%
More